Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Trophos has completed treatment of last patient in a randomized, parallel group, double-blind Phase three efficacy trial evaluating olesoxime in patients suffering from Amyotrophic Lateral Sclerosis (ALS).
Subscribe to our email newsletter
During the trial, Olesoxime is dosed at 330mg oral capsules once a day and riluzole is dosed in both arms at 50mg twice a day.
In total, the company has involved around 500 patients in the trial.
The primary end-point of the study is the overall 18 month survival rate.
Trophos chief medical officer Jean-Louis Abitbol said they are all looking forward with great anticipation to the results of the study, due before the end of the year.